Prilocaine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Prilocaine: Papillary conjunctivitis
One-Sentence Summary
Prilocaine is an amide-type local anesthetic, and it is marketed in Canada in dental, injectable and topical products. The TxGNN model predicts it may be effective for papillary conjunctivitis, but no clinical trials and no publications currently support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Papillary conjunctivitis |
| TxGNN Prediction Score | 0.9978 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 6 of 6) |
| Number of DINs | 6 (marketed: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Prilocaine belongs to the sodium channel-blocking local anesthetics, and its numbing effect on peripheral nerves is well established. A link to allergic or inflammatory ocular surface disease is speculative.
The original indications relate to genital sensitivity and pain, where a topical anesthetic effect is plausible. Papillary conjunctivitis is an inflammatory, often allergic, eye condition, and the data show no clear mechanistic bridge between the two. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It is not supported by trials, literature or demonstrated biology.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
Dosage form and approved-indication text are not recorded for these licences.
| DIN | Product Name |
|---|---|
| 02435276 | 4% Citanest Plain Dental |
| 02325993 | Oraqix |
| 02347695 | 4% Citanest Forte Dental with Epinephrine 1:200,000 |
| 00886858 | EMLA Cream |
| 00393746 | Prilocaine HCl 4% Epinephrine 1:200000 Injection |
| 02057794 | EMLA Patch |
All six are authorizations with valid status. None has been cancelled.
Safety Considerations
- Contraindications flagged in the knowledge graph (graph-derived associations, not package-insert text): hypertension, epilepsy, kidney disease, liver disease, gallbladder disease, diabetes mellitus and diabetic ketoacidosis, coronary artery disease, myocardial infarction, sudden cardiac arrest, heart conduction disease and atrioventricular block, cardiovascular and heart disease, respiratory failure, angle-closure glaucoma, myasthenia gravis and other neuromuscular junction disease, butyrylcholinesterase deficiency, hemoglobinopathy, and hyperthyroidism (including Graves disease and thyrotoxicosis).
- Drug Interactions: 22 interactions were identified. Of the 20 detailed in the data compiled, 18 are rated Major, 1 Moderate (liposomal morphine) and 1 Minor (hyaluronidase). The main Major interactions are:
- Other local anesthetics: lidocaine (systemic and topical), benzocaine (topical), cinchocaine (topical)
- Antimalarials: chloroquine, primaquine, quinine, tafenoquine
- Dapsone (systemic and topical)
- Nitrite and nitric oxide agents: amyl nitrite, nitrous acid, nitric oxide
- Others: metoclopramide, sulfasalazine, rasburicase, silver nitrate (topical), silver sulfadiazine (topical)
Please refer to the package insert for authoritative warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The papillary conjunctivitis prediction has a very high model score but no trials, no publications and no plausible mechanism in the data. It remains at evidence level L5, so it cannot support a repurposing decision.
Among the other predictions for prilocaine, neuralgia (including postherpetic neuralgia) has the strongest support. It reaches L2, with a small Phase 2 open-label study of lidocaine/prilocaine cream (NCT00916942, n=20) and older EMLA studies. That evidence is small and dated, and the combination product makes it hard to attribute any effect to prilocaine alone, so it is better treated as a research question than a ready candidate.
To proceed, the following is needed:
- Mechanism of action data, to assess any biological link to ocular surface disease
- Package insert warnings and contraindications from Health Canada, which are required before any safety screening
- Any preclinical or clinical evidence in conjunctivitis, which does not currently exist
- Review of ocular exposure safety, because the Canadian products are dental, injectable and skin-applied and none is an ophthalmic route
- Consideration of whether to prioritize the neuralgia prediction instead
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.